Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
ALX Oncology Q4 2025 Earnings Call - CD47 Biomarker Validation Drives Evorpacept Strategy and Trial Expansion
ALX used the Q4 2025 call to cement a clear, biomarker-driven strategy for its lead asset evorpacept, citing convergent clinical signals that CD47 overexpression predicts powerful responses across HER...
- Company announced Barb Klencke as permanent Chief Medical Officer after interim role since September 2025, emphasizing clinical leadership continuity.
- Evorpacept (EVO) now has data from over 750 treated patients, and management says the antibody and bispecific combination MOA is clinically validated.
- Randomized Phase 2 gastric cancer subset with HER2-positive, CD47-overexpressing tumors showed a 65% response rate with evorpacept plus trastuzumab versus 26% control, median DOR over 2 years, median PFS 18.4 vs 7 months, hazard ratio 0.39, and median OS 17 vs ~10 months with HR 0.7.
- +13 more takeaways
Arcosa, Inc. Q4 2025 Earnings Call - Barge Sale Sharpens Focus, Utilities and Aggregates to Drive 2026 Growth
Arcosa closed 2025 with record revenue and profitability, then made a decisive portfolio move by agreeing to sell its barge business for $450 million, a deal expected to close in Q2 2026. Management p...
- Record 2025 financials: revenues $2.9 billion, Adjusted EBITDA $583 million, Adjusted EBITDA margin 20.2% (up 280 basis points).
- Company entered definitive agreement to sell barge business for $450 million in cash, expected to close in Q2 2026, buyer Wynnchurch Capital named by management.
- Post-divestiture strategy is focused squarely on construction materials and engineered structures, reducing portfolio complexity and cyclicality.
- +15 more takeaways
Amneal Pharmaceuticals Fourth Quarter 2025 Earnings Call - Launch wave and biosimilars to drive 2026-27 acceleration
Amneal closed 2025 with steady top and bottom line growth and a heavy roster of complex launches that management says will accelerate revenue in 2026 and 2027. Full year revenue reached about $3.0 bil...
- 2025 finish: Full year revenue roughly $3.0 billion, up 8%; adjusted EBITDA $688 million, up 10%; adjusted EPS $0.83, up 43%.
- Q4 specifics: Revenue $814 million, up 11%; adjusted EBITDA over $175 million, up 13%; Q4 EPS $0.21, up 75%.
- 2026 guidance: Revenue growth expected 1% to 4%, adjusted EBITDA up 5% to 10% ($720 million to $760 million), adjusted EPS $0.93 to $1.03, and operating cash flow $325 million to $375 million.
- +13 more takeaways
Natural Resource Partners L.P. Q4 2025 Earnings Call - $39M Sisecam Investment Delays Distribution Increase as Commodities Sit at Cyclical and Generational Lows
Natural Resource Partners reported resilient free cash flow despite brutal commodity markets, generating $46 million in Q4 and $169 million for full-year 2025. Management revised the timing of a plann...
- NRP generated $46 million of free cash flow in Q4 2025 and $169 million for full-year 2025, showing operational cash resilience despite weak commodity prices.
- Management elected to contribute $39 million of capital to the Sisecam Wyoming soda ash joint venture to reduce bank borrowings and shore up the JV, delaying planned distribution increases.
- Sisecam Wyoming has not paid distributions since Q2 2025, and NRP does not expect distributions to resume until soda ash demand rebounds or there is a significant supply response.
- +12 more takeaways
inTEST Corporation Q4 2025 Earnings Call - Diversification cushions semi slump, backlog jumps 36% to $53.9M
inTEST closed 2025 with a strong Q4, driven by non-semi markets and new-product traction, while semiconductor demand remains soft. Revenue of $32.8 million beat guidance, orders exceeded $37 million, ...
- Q4 2025 revenue $32.8 million, above guidance, benefited by about $2 million of orders that slipped from Q3.
- Q4 orders exceeded $37 million, lifting year-end backlog to $53.9 million, up 36% versus year-end 2024 and up 9% sequentially.
- Approximately 60% of the backlog is expected to ship after Q1 2026, giving the company forward visibility into future quarters.
- +13 more takeaways
Docebo Q4 2025 Earnings Call - 365Talents Adds Data Moat, But Growth Reacceleration Depends on Enterprise Execution
Docebo used the Q4 call to sell a clear strategic narrative: the 365Talents acquisition fast-tracks a data moat and agentic workflows that the company says are hard to replicate at enterprise scale. M...
- Docebo completed the 365Talents acquisition and describes integration as phased, with shared customers and an integration already in production.
- 365Talents supplies a skills intelligence layer and agentic tooling, which Docebo calls a strategic data moat that powers automation and learning remediation at scale.
- Management expects three commercial motions: sell 365Talents standalone, attach 365 to Docebo’s customer base, and sell a combined Docebo+365 suite; cross-training of sales began immediately.
- +12 more takeaways
Ready Capital Fourth Quarter 2025 Earnings Call - Aggressive Liquidity Push: $850M Target and 60% CRE Runoff to Fix the Balance Sheet
Ready Capital laid out a clear, urgent cleanup plan, trading short-term earnings and book value for liquidity and a simpler, lower-leverage business going into 2026. Management is executing a two-phas...
- Company plan: comprehensive balance sheet repositioning focused on liquidity, selling underperforming CRE, and repositioning for future growth.
- Free cash target: management targets over $850 million of free cash, intended to exceed 2026 debt maturities.
- Progress to date: approximately $380 million generated since start of Q4, from about $130 million of portfolio sales and $250 million from runoff and asset resolutions.
- +12 more takeaways
ANI Pharmaceuticals Inc. Q4 2025 Earnings Call - Cortrophin Gel to Drive Over $1B 2026 with 90-Person Gout Push
ANI closed 2025 with a clear transformation underway: Cortrophin Gel is the growth engine and the company is leaning into it aggressively. Management set 2026 guidance above $1 billion in revenue, dri...
- Company delivered record 2025 results: total revenues $883.4M, up 44% year-over-year; adjusted non-GAAP EBITDA $229.8M, up 47%.
- Cortrophin Gel was the primary growth driver: 2025 net revenue $347.8M, up 76% year-over-year; Q4 Cortrophin revenue $111.4M, up 88% year-over-year.
- ANI guided 2026 net revenue $1.055B to $1.115B, implying roughly 19%–26% growth year-over-year, with rare disease expected to be ~60% of revenue.
- +16 more takeaways
Photronics Fiscal Q1 2026 Earnings Call - High-end IC demand lifts margins and forces elevated CapEx for U.S. and Korea expansion
Photronics beat expectations in fiscal Q1 2026 with $225 million in revenue, driven by a surge in high-end IC demand in Asia that produced a second consecutive quarterly record for high-end IC revenue...
- Revenue exceeded expectations at $225 million, up 4% sequentially and 6% year-over-year.
- IC revenue was $165 million, up 7% year-over-year; high-end IC revenue hit a record $71 million, up 19% year-over-year.
- FPD (flat panel display) revenue was $60 million, up 3% year-over-year, with stronger mainstream demand in China IT displays.
- +14 more takeaways
MidCap Financial Investment Corporation Q4 2025 Earnings Call - Board launches $100M buyback and trims dividend to $0.31
MidCap delivered a mixed quarter: cash earnings held up with NII of $0.39 per share, but GAAP swung to a loss of $0.14 per share and NAV slid to $14.18, down 3.3% quarter over quarter. Management blam...
- Board authorized a new $100 million stock repurchase program, increasing total repurchase capacity to $107.9 million including existing authorization.
- Management repurchased ~1.1 million shares in Q4 at an average discount of 18% for $12.9 million, producing about $0.03 per share of NAV accretion.
- Quarterly dividend was reduced to $0.31 per share, declared Feb 25, 2026, record date Mar 10, payable Mar 26, reflecting revised long-term earnings power amid lower base rates and tighter spreads.
- +12 more takeaways